Player FM - Internet Radio Done Right
Checked 2M ago
Lisätty four vuotta sitten
Sisällön tarjoaa Cambridge Healthtech Institute. Cambridge Healthtech Institute tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
The Chain: Protein Engineering Podcast
Merkitse kaikki (ei-)toistetut ...
Manage series 2967424
Sisällön tarjoaa Cambridge Healthtech Institute. Cambridge Healthtech Institute tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
…
continue reading
71 jaksoa
Merkitse kaikki (ei-)toistetut ...
Manage series 2967424
Sisällön tarjoaa Cambridge Healthtech Institute. Cambridge Healthtech Institute tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
…
continue reading
71 jaksoa
Kaikki jaksot
×T
The Chain: Protein Engineering Podcast

In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML. LINKS: Bionavigen A-Alpha Bio Specifica…
T
The Chain: Protein Engineering Podcast

1 Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field 42:34
November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs, and where he sees ADCs heading in the future. LINKS: Bionavigen NEXT Oncology…
T
The Chain: Protein Engineering Podcast

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more. LINKS: Bionavigen ImmunoGen…
T
The Chain: Protein Engineering Podcast

September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from small molecules to biologics, and the major differences between doing a postdoc in academia versus in the industry.…
T
The Chain: Protein Engineering Podcast

In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such as GPCRs, and certain properties that AI can optimize better.…
T
The Chain: Protein Engineering Podcast

In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he’s most excited about, recent advancements that have caught his attention, and the new directions for him and his lab.…
T
The Chain: Protein Engineering Podcast

1 Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype 1:03:57
1:03:57
Toista Myöhemmin
Toista Myöhemmin
Listat
Tykkää
Tykätty1:03:57
his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo Nordisk take on where AI/ML has the biggest impact, what the hype is in the use of AI/ML in antibody discovery, how new AI/ML methods are being benchmarked against traditional discovery methods, and what controls should be used in an AI/ML discovery or optimization campaign.…
T
The Chain: Protein Engineering Podcast

1 Episode: 61 - Tomoyuki Igawa Discusses Leadership and His Experiences in Discovery and Development 55:04
In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, speaks with Tomoyuki Igawa, PhD, chief executive officer, Chugai Pharmabody Research in Singapore, about his 20+ years of experience in drug discovery and development. Igawa possesses a unique perspective that has allowed him and his team to develop innovative concepts, such as recycling sweeping antibodies and bispecific platforms. He discusses how the discovery and development organizations work together to provide a steady supply of products, how he builds the right team when starting a new project, and how to keep team members engaged and motivated. He also offers advice for young scientists on the importance of enjoying their work and how to maintain work-life balance.…
T
The Chain: Protein Engineering Podcast

1 Episode: 60 - Lesley Millar-Nicholson on Technology Licensing, Navigating Patents, and Building Teams 48:14
This month The Chain shares a recent episode of the Lab Rats to Unicorns podcast. Lab Rats to Unicorns, hosted by John Flavin, aims to demystify the process of creating a great company in the life sciences, biotech, medtech, clean energy, and beyond. In this episode, Flavin speaks with Lesley Millar-Nicholson, executive director of MIT’s Technology Licensing Office (TLO). Millar-Nicholson discusses the role of the TLO, what happens after a patent is filed and licensed to a company or start-up, how she got her start in the field, and her journey from Scotland to the U.S. She also delves into finding the right people for the best team, the importance of a diverse workforce and awareness, and being around science as a non-scientist.…
T
The Chain: Protein Engineering Podcast

In this month’s episode of The Chain, host Ben Hackel, professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Gabriel Rocklin, assistant professor of Pharmacology at Northwestern University, about two recently published papers from Rocklin’s lab: one on advancing the ability to design challenging typologies and one on developing and leveraging a new technique on high-throughput protein biophysics. Rocklin shares the journey from ideation to realization of the research process, the inspiration that motivated the work, and interesting results and technological advancements discovered along the way. He also talks about the opportunities emerging from his team’s research and the challenges that still need overcoming, as well as offers advice for future scientists interested in protein biophysics.…
T
The Chain: Protein Engineering Podcast

1 Episode: 58 - Janine Schuurman Reflects on the Key Lessons and Accomplishments of Her 20-Year Career 55:05
How does one maintain innovation in the antibody industry? In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, talks with Janine Schuurman, PhD, president of The Antibody Society, independent biotech consultant and founder of Lust for Life Sciences, about her inspiration to get into antibody engineering, her impressive career at Genmab, advice for a productive work environment, and her current work. Dr. Schuurman also shares insights on staying innovative, how to deal with the challenges of the industry, why young scientists should not be afraid to fail, as well as her plans as the new president of The Antibody Society. Links: Lust for Life Sciences: https://www.lustforlifescience.com/ The Antibody Society: https://www.antibodysociety.org/ FairJourney Biologics: https://fjbio.com/…
T
The Chain: Protein Engineering Podcast

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.…
T
The Chain: Protein Engineering Podcast

1 Episode: 56 - Thomas Sakmar on the Golden Age for the Application of Biologics to GPCR Pharmacology 44:38
What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits, his early work with rhodopsin, and the impact of crystallography and structural work. He also shares how he got started with molecular biology training, as well as his thoughts on the state-of-the art for both biologics and small molecules in drug discovery. LINKS: Rockefeller University: https://www.rockefeller.edu GlaxoSmithKline: https://www.gsk.com/en-gb/…
T
The Chain: Protein Engineering Podcast

In this episode of The Chain, Richard Bonneau, PhD, and Marcel Hop, PhD, of Genentech interview Tala Fakhouri, PhD, of the FDA on her thoughts on the discussion paper, “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biologic Products” and the evolving role of AI/ML to create models and inform decisions in biopharmaceutical development and regulatory submissions. Dr. Fakhouri also discusses the impact AI/ML models could have on clinical trial conduct, patient enrollment, patient selection, and data interpretation. She also talks about the next steps to get the right processes in place and why transparency is important to establish trust with patients about AI/ML tools.…
T
The Chain: Protein Engineering Podcast

1 Episode: 54 - Enkelejda Miho on the Current State of AI: Drug Development, Research, and the Future 29:20
With the whirlwind development of AI, it can be difficult to keep track of its uses in both research and the market. In this episode of The Chain podcast, host Ben Hackel, Professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Enkelejda “Ledi” Miho, Professor of Digital Life Sciences at the University of Applied Sciences Northwestern Switzerland FHNW, who breaks down the current state of AI and its role in drug development. She talks about the opportunities of AI and drug discovery and how digital biomarkers and molecular data are helping with personalized medicine. Miho also discusses the challenges of advancing AI, why having an “adisciplinary” approach is the key to assembling the right team, and how to design studies to be as broadly robust as possible, as well as the advancements of her and her team’s own research.…
Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.